00:47 , Feb 23, 2019 |  BioCentury  |  Tools & Techniques

Modeling now for precision later

GNS Healthcare Inc. is building a platform that aims to make value-based payment models unnecessary by giving companies a way to know which patients will respond before they even launch the drug. While drug companies...
23:26 , Feb 22, 2019 |  BC Extra  |  Company News

ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy

Based on the number of years of life it adds, spinal muscular atrophy therapy Zolgensma onasemnogene abeparvovec (AVXS-101) would be cost effective if priced under $1.5 million per year, according to an evidence report released...
22:55 , Feb 22, 2019 |  BioCentury  |  Finance

MPM keeps building

MPM Capital’s new $400 million BioVentures 2018 fund will complement the firm’s cancer-focused initiatives and enable it to continue its company building strategy. BioVentures 2018 closed on Feb. 21 and follows in the footsteps of...
21:51 , Feb 22, 2019 |  BioCentury  |  Emerging Company Profile

Gyroscope complements dry AMD

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators. On Feb. 19, Gyroscope...
18:52 , Feb 22, 2019 |  BC Week In Review  |  Company News

Generic Suboxone products enter U.S. market

At least three companies have launched in the U.S. generic versions of opioid dependence drug Suboxone buprenorphine/naloxone sublingual film from Indivior plc (LSE:INDV). The generic Suboxone manufacturers include Alvogen Inc. (Pinebrook, N.J.), the Sandoz unit...
17:00 , Feb 22, 2019 |  BC Week In Review  |  Company News

Novartis plans to incubate disruptive health-tech companies in Asia

Novartis AG (NYSE:NVS; SIX:NOVN) plans to incubate health technology start-ups in Asia. The pharma aims to partner with start-ups within big data, machine learning and telemedicine technologies to enhance healthcare delivery avenues and map the...
02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
23:49 , Feb 21, 2019 |  BC Week In Review  |  Clinical News

Partial hold for Phase I of Xencor's blood cancer bispecific

Xencor Inc. (NASDAQ:XNCR) said FDA placed a partial clinical hold on a Phase I trial of XmAb14045 following two patient deaths that were considered possibly related to treatment with the bispecific antibody against CD3 and...
19:01 , Feb 21, 2019 |  BC Innovations  |  Translation in Brief

Bugging inflammation in lung cancer

An MIT study linking the lung microbiome to inflammation offers new therapeutic strategies for treating lung cancer and a mechanistic rationale for testing cytokine inhibitors in the disease, a tack Novartis AG (NYSE:NVS; SIX:NOVN) has...
20:01 , Feb 20, 2019 |  BC Extra  |  Clinical News

Partial hold for Phase I of Xencor's blood cancer bispecific

Xencor Inc. (NASDAQ:XNCR) said FDA placed a partial clinical hold on a Phase I trial of XmAb14045 following two patient deaths that were considered possibly related to treatment with the bispecific antibody against CD3 and...